3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
19
Neoplasm Metastasis
3
Neoplasms
2
Bulbo-Spinal Atrophy, X-Linked
2
Salivary Gland Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Metastatic Disease
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Ovarian Neoplasms
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Bites and Stings
1
Advanced Solid Tumor
1
Adenocarcinoma
1
Interventions
pembrolizumab
44
Carboplatin
35
Paclitaxel
27
Specimen Handling
18
Cyclophosphamide
16
Capecitabine
16
Magnetic Resonance Spectroscopy
14
sacituzumab govitecan
13
Gemcitabine
13
Taxes
12
Biopsy
12
130-nm albumin-bound paclitaxel
11
Albumin-Bound Paclitaxel
9
Doxorubicin
8
olaparib
7
Nivolumab
7
fludarabine
6
Cisplatin
6
eribulin
5
atezolizumab
5
Radiotherapy
5
Docetaxel
5
durvalumab
4
Fulvestrant
4
Epirubicin
4
Bevacizumab
4
veliparib
3
famitinib
3
abemaciclib
3
Vinorelbine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
abiraterone
×
90 days
×
Clear all
No trials found.